Predictive OncologyPOAI
POAI
About: Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Pittsburgh segment that provides services which include the application of AI using its proprietary biobank of 150,000+ tumor samples. It also creates proprietary 3D culture models used in drug development; Birmingham segment that provides contract services and research focused on solubility improvements, stability studies, and protein production; and Eagan segment that produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. It derives maximum revenue from Eagan Segment.
Employees: 24
0
Funds holding %
of 7,439 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
0% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]
0.53% less ownership
Funds ownership: 2.56% [Q1] → 2.04% (-0.53%) [Q2]
19% less funds holding
Funds holding: 16 [Q1] → 13 (-3) [Q2]
46% less capital invested
Capital invested by funds: $281K [Q1] → $150K (-$130K) [Q2]
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
Research analyst outlook
We haven’t received any recent analyst ratings for POAI.
Financial journalist opinion
Neutral
GlobeNewsWire
1 week ago
PREDICTIVE ONCOLOGY INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Predictive Oncology Inc. - POAI
NEW ORLEANS, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Predictive Oncology Inc. (NasdaqCM: POAI) to Renovaro Inc. (NasdaqCM: RENB). Under the terms of the binding letter of intent, Predictive Oncology will be merged into Renovaro in exchange for a newly created series of preferred stock of Renovaro. The preferred stock will be issued to shareholders of Predictive Oncology in a 1:1 exchange for their existing Predictive Oncology common stock. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Neutral
GlobeNewsWire
1 week ago
Predictive Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update
PITTSBURGH, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, and CLIA laboratory to accelerate oncologic drug discovery and enable drug development, today reported financial and operating results for the quarter ended June 30, 2025, and provided a corporate update. The Company reported a loss from continuing operations of approximately $2.0 million.
Neutral
GlobeNewsWire
1 month ago
Predictive Oncology Announces $10M Share Purchase Agreement in Partnership with Yorkville Advisors to Advance AI-Driven Drug Discovery and Repurposing
PITTSBURGH, July 08, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, announced today that it has entered into a standby equity purchase agreement (“SEPA”) with YA II PN, LTD, an investment fund managed by Yorkville Advisors Global, LP (“Yorkville”). Predictive Oncology expects the partnership to provide an efficient and flexible source of funding, enabling the company to progress its ongoing drug discovery, biomarker discovery and drug repurposing initiatives, and business development opportunities with leading biopharmaceutical companies, leveraging its novel AI and machine learning capabilities.
Neutral
GlobeNewsWire
2 months ago
Predictive Oncology Develops Functional 3D Organoid Models Exclusively for Labcorp
Models provide highly relevant species-specific data, predict in vivo drug clearance/transport, and support preclinical analysis of cancer therapies Models provide highly relevant species-specific data, predict in vivo drug clearance/transport, and support preclinical analysis of cancer therapies
Neutral
GlobeNewsWire
3 months ago
Court Denies Renovaro Motion for an Expedited Trial in July
PITTSBURGH, May 27, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, today issued the following statement regarding its dispute with Renovaro, Inc.
Neutral
GlobeNewsWire
3 months ago
AI Meets Genomics: Predictive Oncology Breakthrough Coincides with Regeneron's $256M 23andMe Acquisition
Company Leverages More Than Twenty Years of Drug Response Data Derived from Massive Biobank of Live Cell Tumor Samples Company Leverages More Than Twenty Years of Drug Response Data Derived from Massive Biobank of Live Cell Tumor Samples
Neutral
GlobeNewsWire
3 months ago
Predictive Oncology Inc. Issues Shareholder Letter Titled, "Revolutionizing Medicine: AI-Driven Biomarker and Drug Discovery for Precision Health"
Latest developments expand Predictive's AI-driven drug discovery platform to include biomarker discovery and drug repurposing
Neutral
GlobeNewsWire
3 months ago
Predictive Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update
PITTSBURGH, May 15, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, and CLIA laboratory to accelerate oncologic drug discovery and enable drug development, today reported financial and operating results for the quarter ended March 31, 2025, and provided a corporate update. The Company reported a loss from continuing operations of approximately $2.3 million on total revenue of $110,310 for the quarter.
Neutral
GlobeNewsWire
4 months ago
Predictive Oncology Reports Year-End 2024 Financial Results and Provides Corporate Update
PITTSBURGH, April 01, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, and CLIA laboratory, to accelerate oncologic drug discovery and enable drug development, today reported financial and operating results for the quarter ended December 31, 2024, and provided a corporate update. The Company reported a loss from continuing operations of approximately $10.8 million on total revenue of $1.6 million for the year ended December 31, 2024.
Neutral
GlobeNewsWire
5 months ago
Predictive Oncology Successfully Develops Predictive Models Derived from Never-Before-Seen Compounds for Prevalent Cancer Indications Including Breast, Colon and Ovary
Company successfully developed predictive models derived from 21 unique compounds from the Natural Products Discovery Core at the University of Michigan
Charts implemented using Lightweight Charts™